Brokerage Firm Rating Update on Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) : The consensus on Catalyst Pharmaceuticals (CPRX) based on 4 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Catalyst Pharmaceuticals (CPRX) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $6 and the lowest price target forecast is $1. The average forecast of all the analysts is $3.63 and the expected standard deviation is $2.29.


For the current week, the company shares have a recommendation consensus of Buy.

Catalyst Pharmaceuticals (NASDAQ:CPRX): stock was range-bound between the intraday low of $1.01 and the intraday high of $1.06 after having opened at $1.05 on Wednesdays session. The stock finally closed in the red at $1.05, a loss of -2.88%. The stock remained in the red for the whole trading day. The total traded volume was 520,783 shares. The stock failed to cross $1.06 in Wednesdays trading. The stocks closing price on Thursday was $1.04.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.